Fig. 4

Fluorescent in situ hybridization to detect animally-directed movement of dazl RNA. (A-A′) In DMSO control embryos, dazl RNPs are transported toward the animal pole (79% with transport, n = 19 ). (B-B′) Movement toward the animal pole appears unaffected by treatment with nocodazole (86% with transport, n = 21 ). (C-C′) Injection of latrunculin A inhibits the transport of dazl RNPs toward the animal pole region (31% with transport, n = 13 ; the effects of injected latrunculin A are expected to be non-uniform due to inhibition of ooplasmic movement and resulting uneven drug distribution, as has been previously observed). Top and bottom panels present different focal planes of the same embryos, focusing on side edge and frontal cortex, respectively. Movement of dazl RNA along the cortex is best visualized in the frontal cortex (extent of RNA movement is highlighted by brackets). Nocodazole exposure was initiated at 5 mpf and latrunculin A injection was carried out at 7–12 mpf. All embryos were fixed at 60 mpf. Injection of carrier solvent to control for latrunculin A injection did not affect dazl RNP transport (85% with transport, n = 7).